Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9056848 | 0.88 | THRB (0.64) | THRBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7765194 | 0.86 | MMP1 (0.35) | THRBCYP3A4CYP2C9CYP2C19MMP1 | |
| SCHEMBL25660393 | 0.79 | THRB (0.39) | THRBCYP2C9CYP2C19 | |
| SCHEMBL2488687 | 0.79 | THRB (0.42) | THRBCYP3A4CYP2C9CYP2C19MMP1 | |
| SCHEMBL6433430 | 0.79 | THRB (0.39) | THRBCYP3A4CYP2C9CYP2C19MMP1 | |
| SCHEMBL27864827 | 0.77 | MEN1 (0.35) | THRBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5181141 | 0.76 | THRB (0.81) | THRBCYP3A4CYP2C9CYP2C19MMP1 | |
| SCHEMBL5180385 | 0.76 | THRB (0.81) | THRBCYP3A4CYP2C9CYP2C19MMP1 | |
| SCHEMBL52741 | 0.76 | THRB (0.81) | THRBCYP3A4CYP2C9CYP2C19MMP1 | |
| SCHEMBL4948620 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118119613-A | Benzimidazoles as IL-17 modulators | 詹森药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | THRB 4214/4885CYP3A4 319/4885CYP2C9 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.